EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma

Yosuke Inukai iD, Kenta Yamamoto iD, Takashi Honda, Shinya Yokoyama iD, Takanori Ito iD, Norihiro Imai iD, Yoji Ishizu iD, Masanao Nakamura iD, Masatoshi Ishigami, Hiroki Kawashima

Cancers · 26.04.2024 · 16 (9) · 1675

DOI: 10.3390/cancers16091675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 26.04.2024. Verfasst von Yosuke Inukai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the 39th Grant from The Nitto Foundation for Kenta Yamamoto, JST [Moonshot R&D], JST [Moonshot R&D].

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of atezolizumab and bevacizumab has become the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). However, no studies have reported on specific intestinal microbiota associated with the efficacy of atezolizumab and bevacizumab. In this study, we analyzed fecal samples collected before treatment to investigate the relationship between the intestinal microbiome and the efficacy of atezolizumab and bevacizumab. A total of 37 patients with advanced HCC who were treated with atezolizumab and bevacizumab were enrolled. Fecal samples were collected from the patients, and they were divided into responder (n = 28) and non-responder (n = 9) groups. We compared the intestinal microbiota of the two groups and analyzed the intestinal bacteria associated with prognosis using QIIME2. The alpha and beta diversities were not significantly different between both groups, and the proportion of microbiota was similar. The relative abundance of Bacteroides stercoris and Parabacteroides merdae was higher in the responder group than in the non-responder group. When the prognosis was analyzed by the presence or absence of those bacteria, patients without both had a significantly poorer prognosis. Differences in intestinal microbiome are involved in the therapeutic effect of atezolizumab and bevacizumab.

Schlagwörter

Stichwörter der Autor:innen

atezolizumabbevacizumabhepatocellular carcinomaimmune checkpoint inhibitormicrobiome

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan.

ORCID-Profile: Yosuke Inukai, Kenta Yamamoto, Shinya Yokoyama, Takanori Ito, Norihiro Imai, Yoji Ishizu, Masanao Nakamura

Förderung

  • the 39th Grant from The Nitto Foundation for Kenta Yamamoto
  • JST [Moonshot R&D]
  • JST [Moonshot R&D]

Zitieren

APA

Inukai, Y., Yamamoto, K., Honda, T., Yokoyama, S., Ito, T., Imai, N., Ishizu, Y., Nakamura, M., Ishigami, M., & Kawashima, H. (2024). Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma. Cancers, 16(9), 1675. https://doi.org/10.3390/cancers16091675

Vancouver

Inukai Y, Yamamoto K, Honda T, Yokoyama S, Ito T, Imai N, et al. Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma. Cancers. 2024;16(9):1675. doi:10.3390/cancers16091675

BibTeX
@article{Inukai2024,
  author = {Inukai, Yosuke and Yamamoto, Kenta and Honda, Takashi and Yokoyama, Shinya and Ito, Takanori and Imai, Norihiro and Ishizu, Yoji and Nakamura, Masanao and Ishigami, Masatoshi and Kawashima, Hiroki},
  title = {Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1675},
  doi = {10.3390/cancers16091675}
}
Kostenlos starten →